Performance Evaluation of VIDAS® Diagnostic Assays Detecting Anti-Chikungunya Virus IgM and IgG Antibodies: An International Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients and Samples
2.2. Study Design and Definitions
2.3. VIDAS® Assays
2.4. Competitor Enzyme-Linked Immunosorbent Assays (ELISAs)
2.5. Rapid Diagnostic Test (RDT)
2.6. Real-Time RT-PCR Assays
2.7. Precision Experiments
2.8. Cross-Reactivity Experiments
2.9. Statistical Analyses
3. Results
3.1. Patients’ Characteristics
3.2. Clinical Performance of the VIDAS® Anti-CHIKV IgM and IgG Assays
3.2.1. Clinical Sensitivity
3.2.2. Concordance of the VIDAS® CHIKV IgM and IgG Assays with Competitor ELISA in the Total Study Population
3.2.3. Comparison of Assay Concordance of the VIDAS® CHIKV Assays and RDT with Competitor ELISA
3.3. Analytical Performance of the VIDAS® CHIKV IgM and IgG Assays
3.3.1. Assay Precision
3.3.2. Assay Cross-Reactivity
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Vairo, F.; Haider, N.; Kock, R.; Ntoumi, F.; Ippolito, G.; Zumla, A. Chikungunya: Epidemiology, Pathogenesis, Clinical Features, Management, and Prevention. Infect. Dis. Clin. N. Am. 2019, 33, 1003–1025. [Google Scholar] [CrossRef]
- Robinson, M.C. An Epidemic of Virus Disease in Southern Province, Tanganyika Territory, in 1952–1953—I: Clinical Features. Trans R. Soc. Trop. Med. Hyg. 1955, 49, 28–32. [Google Scholar] [CrossRef]
- Deeba, F.; Haider, M.S.H.; Ahmed, A.; Tazeen, A.; Faizan, M.I.; Salam, N.; Hussain, T.; Alamery, S.F.; Parveen, S. Global Transmission and Evolutionary Dynamics of the Chikungunya Virus. Epidemiol. Infect. 2020, 148, e63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leparc-Goffart, I.; Nougairede, A.; Cassadou, S.; Prat, C.; de Lamballerie, X. Chikungunya in the Americas. Lancet 2014, 383, 514. [Google Scholar] [CrossRef] [PubMed]
- Natrajan, M.S.; Rojas, A.; Waggoner, J.J. Beyond Fever and Pain: Diagnostic Methods for Chikungunya Virus. J. Clin. Microbiol. 2019, 57, e00350-19. [Google Scholar] [CrossRef] [Green Version]
- Álvarez-Argüelles, M.E.; Alba, S.R.; Pérez, M.R.; Riveiro, J.A.B.; García, S.M.; Álvarez-Argüelles, M.E.; Alba, S.R.; Pérez, M.R.; Riveiro, J.A.B.; García, S.M. Diagnosis and Molecular Characterization of Chikungunya Virus Infections; IntechOpen: London, UK, 2019; ISBN 978-1-78923-890-7. [Google Scholar]
- Silva, J.V.J.; Ludwig-Begall, L.F.; Oliveira-Filho, E.F.; de Oliveira, R.A.S.; Durães-Carvalho, R.; Lopes, T.R.R.; Silva, D.E.A.; Gil, L.H.V.G. A Scoping Review of Chikungunya Virus Infection: Epidemiology, Clinical Characteristics, Viral Co-Circulation Complications, and Control. Acta Trop. 2018, 188, 213–224. [Google Scholar] [CrossRef]
- Paixão, E.S.; Teixeira, M.G.; Rodrigues, L.C. Zika, Chikungunya and Dengue: The Causes and Threats of New and Re-Emerging Arboviral Diseases. BMJ Glob. Health 2018, 3, e000530. [Google Scholar] [CrossRef] [Green Version]
- Furuya-Kanamori, L.; Liang, S.; Milinovich, G.; Soares Magalhaes, R.J.; Clements, A.C.A.; Hu, W.; Brasil, P.; Frentiu, F.D.; Dunning, R.; Yakob, L. Co-Distribution and Co-Infection of Chikungunya and Dengue Viruses. BMC Infect. Dis. 2016, 16, 84. [Google Scholar] [CrossRef] [Green Version]
- Mota, M.L.; Dos Santos Souza Marinho, R.; Duro, R.L.S.; Hunter, J.; de Menezes, I.R.A.; de Lima Silva, J.M.F.; Pereira, G.L.T.; Sabino, E.C.; Grumach, A.; Diaz, R.S.; et al. Serological and Molecular Epidemiology of the Dengue, Zika and Chikungunya Viruses in a Risk Area in Brazil. BMC Infect. Dis. 2021, 21, 704. [Google Scholar] [CrossRef] [PubMed]
- Ohst, C.; Saschenbrecker, S.; Stiba, K.; Steinhagen, K.; Probst, C.; Radzimski, C.; Lattwein, E.; Komorowski, L.; Stöcker, W.; Schlumberger, W. Reliable Serological Testing for the Diagnosis of Emerging Infectious Diseases. Adv. Exp. Med. Biol. 2018, 1062, 19–43. [Google Scholar] [CrossRef]
- Vu, D.M.; Jungkind, D.; LaBeaud, A.D. Chikungunya Virus. Clin. Lab. Med. 2017, 37, 371–382. [Google Scholar] [CrossRef] [PubMed]
- Pan American Health Organization. Tool for the Diagnosis and Care of Patients with Suspected Arboviral Diseases. Available online: https://iris.paho.org/bitstream/handle/10665.2/33895/9789275119365_eng.pdf?sequence=1&isAllowed=y (accessed on 15 October 2022).
- Ribeiro, M.O.; Godoy, D.T.; Fontana-Maurell, M.; Costa, E.M.; Andrade, E.F.; Rocha, D.R.; Ferreira, A.G.P.; Brindeiro, R.; Tanuri, A.; Alvarez, P. Analytical and Clinical Performance of Molecular Assay Used by the Brazilian Public Laboratory Network to Detect and Discriminate Zika, Dengue and Chikungunya Viruses in Blood. Braz. J. Infect. Dis. 2021, 25, 101542. [Google Scholar] [CrossRef]
- Simon, F.; Javelle, E.; Cabie, A.; Bouquillard, E.; Troisgros, O.; Gentile, G.; Leparc-Goffart, I.; Hoen, B.; Gandjbakhch, F.; Rene-Corail, P.; et al. French Guidelines for the Management of Chikungunya (Acute and Persistent Presentations). November 2014. Med. Mal. Infect. 2015, 45, 243–263. [Google Scholar] [CrossRef] [PubMed]
- Cunha, R.V.; da Trinta, K.S. Chikungunya Virus: Clinical Aspects and Treatment—A Review. Mem. Inst. Oswaldo Cruz 2017, 112, 523–531. [Google Scholar] [CrossRef]
- World Health Organization. Guidelines on Clinical Management of Chikungunya Fever. Available online: https://www.who.int/publications-detail-redirect/guidelines-on-clinical-management-of-chikungunya-fever (accessed on 12 October 2022).
- Centers for Disease Control and Prevention. Diagnostic Testing|Chikungunya Virus|CDC. Available online: https://www.cdc.gov/chikungunya/hc/diagnostic.html (accessed on 13 October 2022).
- Johnson, B.W.; Russell, B.J.; Goodman, C.H. Laboratory Diagnosis of Chikungunya Virus Infections and Commercial Sources for Diagnostic Assays. J. Infect. Dis. 2016, 214, S471–S474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Andrew, A.; Navien, T.N.; Yeoh, T.S.; Citartan, M.; Mangantig, E.; Sum, M.S.H.; Ch’ng, E.S.; Tang, T.-H. Diagnostic Accuracy of Serological Tests for the Diagnosis of Chikungunya Virus Infection: A Systematic Review and Meta-Analysis. PLoS Negl. Trop. Dis. 2022, 16, e0010152. [Google Scholar] [CrossRef]
- Chua, C.-L.; Sam, I.-C.; Merits, A.; Chan, Y.-F. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera. PLoS Negl. Trop. Dis. 2016, 10, e0004960. [Google Scholar] [CrossRef] [Green Version]
- Mascarenhas, M.; Garasia, S.; Berthiaume, P.; Corrin, T.; Greig, J.; Ng, V.; Young, I.; Waddell, L. A Scoping Review of Published Literature on Chikungunya Virus. PLoS ONE 2018, 13, e0207554. [Google Scholar] [CrossRef]
- Johnson, B.W.; Goodman, C.H.; Holloway, K.; de Salazar, P.M.; Valadere, A.M.; Drebot, M.A. Evaluation of Commercially Available Chikungunya Virus Immunoglobulin M Detection Assays. Am. J. Trop. Med. Hyg. 2016, 95, 182–192. [Google Scholar] [CrossRef] [Green Version]
- Kikuti, M.; Tauro, L.B.; Moreira, P.S.S.; Nascimento, L.C.J.; Portilho, M.M.; Soares, G.C.; Weaver, S.C.; Reis, M.G.; Kitron, U.; Ribeiro, G.S. Evaluation of Two Commercially Available Chikungunya Virus IgM Enzyme-Linked Immunoassays (ELISA) in a Setting of Concomitant Transmission of Chikungunya, Dengue and Zika Viruses. Int. J. Infect. Dis. 2020, 91, 38–43. [Google Scholar] [CrossRef] [Green Version]
- Woods, C.R. False-Positive Results for Immunoglobulin M Serologic Results: Explanations and Examples. J. Pediatr. Infect. Dis. Soc. 2013, 2, 87–90. [Google Scholar] [CrossRef]
- Landry, M.L. Immunoglobulin M for Acute Infection: True or False? Clin. Vaccine Immunol. 2016, 23, 540–545. [Google Scholar] [CrossRef] [Green Version]
- Prat, C.M.; Flusin, O.; Panella, A.; Tenebray, B.; Lanciotti, R.; Leparc-Goffart, I. Evaluation of Commercially Available Serologic Diagnostic Tests for Chikungunya Virus. Emerg. Infect. Dis. 2014, 20, 2129–2132. [Google Scholar] [CrossRef]
- Akahata, W.; Yang, Z.-Y.; Andersen, H.; Sun, S.; Holdaway, H.A.; Kong, W.-P.; Lewis, M.G.; Higgs, S.; Rossmann, M.G.; Rao, S.; et al. A Virus-like Particle Vaccine for Epidemic Chikungunya Virus Protects Nonhuman Primates against Infection. Nat. Med. 2010, 16, 334–338. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yap, M.L.; Klose, T.; Urakami, A.; Hasan, S.S.; Akahata, W.; Rossmann, M.G. Structural Studies of Chikungunya Virus Maturation. Proc. Natl. Acad. Sci. USA 2017, 114, 13703–13707. [Google Scholar] [CrossRef] [Green Version]
- Clinical & Laboratory Standards Institute. EP05-A3: Evaluating Quantitative Measurement Precision, 3rd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2014; Available online: https://clsi.org/standards/products/method-evaluation/documents/ep05/ (accessed on 27 October 2021).
- Clinical & Laboratory Standards Institute. EP12-A2: User Protocol for Evaluation of Qualitative Test Performance, 2nd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008; Available online: https://clsi.org/standards/products/method-evaluation/documents/ep12/ (accessed on 12 October 2022).
- Khan, A.H.; Morita, K.; Parquet, M.D.C.; Hasebe, F.; Mathenge, E.G.M.; Igarashi, A. Complete Nucleotide Sequence of Chikungunya Virus and Evidence for an Internal Polyadenylation Site. J. Gen. Virol. 2002, 83, 3075–3084. [Google Scholar] [CrossRef]
- Lwande, O.W.; Obanda, V.; Bucht, G.; Mosomtai, G.; Otieno, V.; Ahlm, C.; Evander, M. Global Emergence of Alphaviruses That Cause Arthritis in Humans. Infect. Ecol. Epidemiol. 2015, 5, 29853. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Henss, L.; Yue, C.; Kandler, J.; Faddy, H.M.; Simmons, G.; Panning, M.; Lewis-Ximenez, L.L.; Baylis, S.A.; Schnierle, B.S. Establishment of an Alphavirus-Specific Neutralization Assay to Distinguish Infections with Different Members of the Semliki Forest Complex. Viruses 2019, 11, 82. [Google Scholar] [CrossRef] [Green Version]
- Smith, J.L.; Pugh, C.L.; Cisney, E.D.; Keasey, S.L.; Guevara, C.; Ampuero, J.S.; Comach, G.; Gomez, D.; Ochoa-Diaz, M.; Hontz, R.D.; et al. Human Antibody Responses to Emerging Mayaro Virus and Cocirculating Alphavirus Infections Examined by Using Structural Proteins from Nine New and Old World Lineages. mSphere 2018, 3, e00003-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Partidos, C.D.; Paykel, J.; Weger, J.; Borland, E.M.; Powers, A.M.; Seymour, R.; Weaver, S.C.; Stinchcomb, D.T.; Osorio, J.E. Cross-Protective Immunity against o’nyong-Nyong Virus Afforded by a Novel Recombinant Chikungunya Vaccine. Vaccine 2012, 30, 4638–4643. [Google Scholar] [CrossRef] [Green Version]
- Kam, Y.-W.; Pok, K.-Y.; Eng, K.E.; Tan, L.-K.; Kaur, S.; Lee, W.W.L.; Leo, Y.-S.; Ng, L.-C.; Ng, L.F.P. Sero-Prevalence and Cross-Reactivity of Chikungunya Virus Specific Anti-E2EP3 Antibodies in Arbovirus-Infected Patients. PLoS Negl. Trop. Dis. 2015, 9, e3445. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Flies, E.J.; Lau, C.L.; Carver, S.; Weinstein, P. Another Emerging Mosquito-Borne Disease? Endemic Ross River Virus Transmission in the Absence of Marsupial Reservoirs. BioScience 2018, 68, 288–293. [Google Scholar] [CrossRef]
- Paz, S. Climate Change Impacts on West Nile Virus Transmission in a Global Context. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2015, 370, 20130561. [Google Scholar] [CrossRef] [PubMed]
Site | Collection Site | Samples | Collection Time | Testing Site |
---|---|---|---|---|
1 | National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil | Retrospective, follow-up cohort | 18 April 2019–1 November 2019 | Tropical Medicine Institute, Faculty of Medicine of the University of São Paulo, Brazil |
2 | Biospecimen Solutions Pvt Ltd., Sampigehalli, Bangalore, Karnataka, India | Prospective cohort | 24 July 2021– 20 September 2021 | Clinical Affairs Laboratory, bioMérieux, Marcy l’Etoile, France |
3 | Colombia, Dominican Republic, Honduras, and Peru | Retrospective cohort 1 | 28 January 2016–8 September 2020 | Clinical Affairs Laboratory, bioMérieux, Marcy l’Etoile, France |
Competitor ELISA | Name of Assay | Manufacturer |
---|---|---|
IgM 1 | CHIKjj DetectTM IgM ELISA (CHKM-R) | InBios International, Seattle, WA, USA |
NovaLisa Chikungunya Virus IgM µ-capture, ELISA Kit (NOVCHIM0590) | NovaTec Immundiagnostica, Dietzenbach, Germany | |
IgG | Chikungunya virus (CHIKV) (EI 293a-9601 G) | Euroimmun, Lübeck, Germany |
Sample Definition | IgM Competitor ELISA Results 1 | IgG Competitor ELISA Result 2 | CHIKV IgM Agreement Study | CHIKV IgG Agreement Study | |
---|---|---|---|---|---|
InBios | NovaTec | Euroimmun | |||
IgM+/IgG− | positive | positive | negative | PPA | N/A |
IgM+/IgG+ | positive | positive | positive | PPA | PPA |
IgM−/IgG+ | negative | negative | positive | N/A | PPA |
IgM−/IgG− | negative | negative | negative | NPA 3 | NPA 3 |
Characteristics | Total | Site 1 | Site 2 | Site 3 |
---|---|---|---|---|
Centre | - | Brazil | India | France |
Study population, N (%) | 490 (100.0%) | 184 (37.5%) | 47 (9.6%) | 259 (52.9%) 1 |
Age in years, median (range) | 37.0 (15–92) | 41.0 (19–83) | 43.0 (20–83) | 33.0 (15–92) |
Sex, N (%) | ||||
Female | 340 (69.4%) | 124 (67.4%) | 19 (40.4%) | 197 (76.1%) |
Male | 150 (30.6%) | 60 (32.6%) | 28 (59.6%) | 62 (23.9%) |
Study samples, N (%) | 656 (100.0%) | 350 (53.3%) | 47 (7.2%) | 259 (39.5%) |
Assay | Time from Symptom Onset | |||||
---|---|---|---|---|---|---|
Acute Phase | Post-Acute Phase | Chronic Phase | ||||
0–4 Days (n = 75) | 5–10 Days (n = 34) | 11–21 Days (n = 69) | 22–89 Days (n = 31) | >89 Days (n = 56) | ||
VIDAS® CHIKV IgM | n/N 1 (%) | 11/75 (14.7%) | 30/34 (88.2%) | 69/69 (100.0%) | 30/31 (96.8%) | 53/56 (94.6%) |
[95% CI] | [8.4–24.4] | [73.4–95.3] | [94.8–100.0] | [83.3–99.9] | [85.4–98.2] | |
InBios ELISA IgM | n/N 1 (%) | 12/75 (16.0%) | 31/34 (91.2%) | 69/69 (100.0%) | 29/31 (93.5%) | 55/56 (98.2%) |
[95% CI] | [9.4–25.9] | [77.0–97.0] | [94.8–100.0] | [79.3–98.2] | [90.4–100.0] | |
NovaTec ELISA IgM | n/N 1 (%) | 18/75 (24.0%) | 31/34 (91.2%) | 69/69 (100.0%) | 31/31 (100.0%) | 56/56 (100.0%) |
[95% CI] | [15.8–34.8] | [77.0–97.0] | [94.8–100.0] | [88.8–100.0] | [93.6–100.0] | |
VIDAS® CHIKV IgG | n/N 1 (%) | 2/75 (2.7%) | 9/34 (26.5%) | 69/69 (100.0%) | 31/31 (100.0%) | 56/56 (100.0%) |
[95% CI] | [0.3–9.3] | [14.6–43.1] | [94.8–100.0] | [88.8–100.0] | [93.6–100.0] | |
Euroimmun ELISA IgG | n/N 1 (%) | 1/75 (1.3%) | 6/33 (18.2%) 2 | 69/69 (100.0%) | 31/31 (100.0%) | 56/56 (100.0%) |
[95% CI] | [0.0–7.2] | [8.6–34.4] | [94.8–100.0] | [88.8–100.0] | [93.6–100.0] |
VIDAS® CHIKV Assay | Positive Percent Agreement (PPA) | Negative Percent Agreement (NPA) | Overall Percent Agreement (OPA) | |
---|---|---|---|---|
IgM | n/N 1 (%) | 157/161 (97.5%) | 194/194 (100.0%) | 351/355 (98.9%) |
[95% CI] | [93.8–99.3] | [98.1–100.0] | [97.1–99.7] | |
IgG | n/N 1 (%) | 203/204 (99.5%) | 193/194 (99.5%) | 396/398 (99.5%) |
[95% CI] | [97.3–100.0] | [97.2–100.0] | [98.2–99.9] |
Assay | Positive Percent Agreement (PPA) | Negative Percent Agreement (NPA) | Overall Percent Agreement (OPA) | |
---|---|---|---|---|
VIDAS® CHIKVIgM | n/N 1 (%) | 19/19 (100.0%) | 157/157 (100.0%) | 176/176 (100.0%) |
[95% CI] | [82.4–100.0] | [97.7–100.0] | [97.9–100.0] | |
RDT IgM/IgG 2 | n/N 1 (%) | 13/19 (68.4%) | 157/157 (100.0%) | 170/176 (96.6%) |
[95% CI] | [46.0–84.6] | [97.7–100.0] | [92.7–98.7] | |
VIDAS® CHIKVIgG | n/N 1 (%) | 128/129 (99.2%) | 156/157 (99.4%) | 284/286 (99.3%) |
[95% CI] | [95.8–100.0] | [96.5–100.0] | [97.5–100.0] | |
RDT IgM/IgG 2 | n/N 1 (%) | 87/129 (67.4%) | 157/157 (100.0%) | 244/286 (85.3%) |
[95% CI] | [59.0–74.9] | [97.7–100.0] | [80.7–88.9] |
VIDAS® CHIKV Assay | Sample | Measurements (N) | Mean Index | Repeatability (Within-Run Precision) | Within-Laboratory Precision 1 | ||
---|---|---|---|---|---|---|---|
SD | CV (%) | SD | CV (%) | ||||
IgM | High negative | 120 | 0.84 | 0.02 | 2.2 | 0.04 | 5.1 |
Low positive | 120 | 1.39 | 0.03 | 2.5 | 0.06 | 4.6 | |
Moderate positive | 120 | 3.68 | 0.07 | 1.9 | 0.11 | 3.0 | |
IgG | High negative | 120 | 0.92 | 0.05 | 5.0 | 0.07 | 7.4 |
Low positive | 120 | 1.32 | 0.06 | 4.6 | 0.07 | 5.6 | |
Moderate positive | 120 | 5.82 | 0.22 | 3.7 | 0.34 | 5.9 |
Potentially Interfering Infections | Proportion of Cross-Reactions with VIDAS® CHIKV Assays | |
---|---|---|
IgM | IgG | |
Herpes simplex virus (HSV1/2) | 0/10 | 1/10 |
Varicella zoster virus (VZV) | 0/10 | 0/10 |
Cytomegalovirus (CMV) | 0/11 | 0/10 |
Epstein-Barr virus (EBV) | 0/9 | 0/10 |
Influenza virus (IAV/IBV) | 0/12 | 0/12 |
Hepatitis A virus (HAV) | 0/10 | 0/10 |
Hepatitis B virus (HBV) | 0/10 | 0/10 |
Hepatitis C Virus (HCV) | 0/10 | 0/10 |
Parvovirus B19 | 0/6 | 0/10 |
Human immunodeficiency virus (HIV) | 0/10 | 0/10 |
Borrelia burgdorferi | 0/10 | 0/10 |
Plasmodium falciparum | 0/10 | 0/10 |
Toxoplasma gondii | 1/12 | 0/10 |
Leptospira | 0/11 | 0/10 |
Dengue virus (DENV) | 0/10 | 0/10 |
West Nile virus (WNV) | 0/10 | 2/10 |
Yellow fever virus (YFV) | 0/10 | 0/10 |
Zika virus (ZIKV) | 0/11 | 0/10 |
Japanese encephalitis virus (JEV) | 0/5 | n.d. |
Barmah Forest virus (BFV) | 0/2 | 0/3 |
Ross River virus (RRV) | 0/10 | 3/10 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | 0/11 | 0/10 |
Total, n/N (%) | 1/210 (0.48%) | 6/205 (2.93%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pereira, G.M.; Manuli, E.R.; Coulon, L.; Côrtes, M.F.; Ramundo, M.S.; Dromenq, L.; Larue-Triolet, A.; Raymond, F.; Tourneur, C.; Lázari, C.d.S.; et al. Performance Evaluation of VIDAS® Diagnostic Assays Detecting Anti-Chikungunya Virus IgM and IgG Antibodies: An International Study. Diagnostics 2023, 13, 2306. https://doi.org/10.3390/diagnostics13132306
Pereira GM, Manuli ER, Coulon L, Côrtes MF, Ramundo MS, Dromenq L, Larue-Triolet A, Raymond F, Tourneur C, Lázari CdS, et al. Performance Evaluation of VIDAS® Diagnostic Assays Detecting Anti-Chikungunya Virus IgM and IgG Antibodies: An International Study. Diagnostics. 2023; 13(13):2306. https://doi.org/10.3390/diagnostics13132306
Chicago/Turabian StylePereira, Geovana M., Erika R. Manuli, Laurie Coulon, Marina F. Côrtes, Mariana S. Ramundo, Loïc Dromenq, Audrey Larue-Triolet, Frédérique Raymond, Carole Tourneur, Carolina dos Santos Lázari, and et al. 2023. "Performance Evaluation of VIDAS® Diagnostic Assays Detecting Anti-Chikungunya Virus IgM and IgG Antibodies: An International Study" Diagnostics 13, no. 13: 2306. https://doi.org/10.3390/diagnostics13132306